

2+	≥20/ 10視野	≥10/ 100視野	G5
3+	≥100/ 1視野	≥10/1 視野	G9

*相当するガフキー号数

(結核菌検査指針2007)

肺結核患者が喀痰の検査で塗抹陽性を示す場合が他に感染を及ぼす可能性が高いという意味で最も重要な指標である。

集団感染（定義）

「接触者健診の手引き」では以下のように定義されている。「同一の感染源が2家族以上にまたがり、20人以上に感染させた場合をいう。ただし発病者1人は6人が感染を受けた者として感染者数を計算する。」たとえば、1人の患者の接触者の中から2人の結核患者が発生し、他に10人がLTBIと診断されたような場合は、感染者総数は2（発病患者数）×6+10（未発病の潜在性結核者数）=22 となり、この定義に当てはまる集団感染となる。

D O T S

Directly Observed Treatment, Short Course の略語で、患者の規則的な受療（服薬等）を確保し、確実な治癒と耐性菌出現の予防のために行う患者治療の方法。もともとは患者にまとまった量の抗結核薬を所持させることなく、毎日患者に対して医療職員の監督下で服薬させ（少なくとも最初の2ヶ月間）、その機会に必要な助言や指導を行うことであったが、WHOはこれに政府の関与、有症状者を対象にして塗抹検査を用いる患者発見、薬剤の安定的な供給、対策の監視と指導を加えた結核対策戦略のブランドネームとした。もともと途上国で始められたものであるが、米国のような国でもいい成績を挙げ、結核治療の基本的な戦略となっている。現在日本では包括的服薬支援ととられLTBIを含む全ての結核患者の治療に積極的に適用することが求められている。

非結核性抗酸菌症

結核菌は抗酸菌と呼ばれる菌の種類の一つであるが、この種類の菌の中には、環境中に結核菌の他にも多くの菌があることが知られている。これらの菌の大多数に病原性はないが、いくつかの菌種は条件がそろえば病気を起こすことが知られている。その条件とは患者の細胞免疫が非常に下がった場合、結核の遺残病巣や気管支拡張症のような肺の局所に抵抗性の弱い部位がある場合などである。日本では結核が治ったあと後遺症のようにこれらの菌による病気が進展してくることが多かったが、近年は先に結核がなく、塵肺や気管支拡張症などにこの菌による病変が合併することや特別な要因がなく発病することもまれでなくなった。治療法は菌の種類によって異なるが、抗結核薬のいくつかがある程度まで有効であるが、結核のような目覚ましい効果は期待できない。

接触者健康診断（法第17条に基づく健康診断）

感染症法第17条は都道府県知事（政令指定都市では市長、実際は委任されている保健所長）に対して「当該感染症にかかっていると疑うに足りる正当な理由のある者に対し」健康診断を受けることを勧告することができる」と規定されており、勧告に従わない場合には、法律적으로는強制力を持つ措置をすることができる」とされている。この健診のための調査は感染症法第15条に規定される積極的疫学調査に該当し、これも都道府県知事に権限が付与されている（実際は保健所長に委任されている）。調査対象者には必要な調査に協力する努力義務が課せられており、法律に基づく調査として、保健所に対する個人情報提供は、個人情報保護法における個人情報の目的外使用制限の規定から除外される。

5. 参考文献

1. 日本結核病学会予防委員会：医療施設内結核感染対策について。結核2010:85; 477-481
2. 青木正和：結核の院内感染（改訂版）。結核予防会 1999.
3. 青木正和：院内感染防止ガイドライン。結核予防会 1998.
4. 地方医務局長協議会：国立病院・療養所「結核院内感染防止のための指針」。1998.

結核に関する知識や情報を提供しています。

（財）結核予防会結核研究所

〒204-8533 東京都清瀬市松山3-1-24

電話 0424-93-5711 ファックス 0424-92-4600

結核研究所ホームページアドレス：<http://www.jata.or.jp>

Ⅲ 研究成果の刊行に関する一覧表

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Okada M., Kita Y., Nakajima T., Hashimoto S., Nakatani H., Nishimatsu S., Nishida Y., Kanamaru N., Kaneda Y., Takamori Y, McMurray D., Tan EV., Cang ML., Saunderson P. and Cruz ECD.	The study of novel DNA vaccines against tuberculosis: Induction of pathogen -specific CTL in the mouse and monkey models of tuberculosis.	Hum Vaccines and Immunotherapeutics	9(3)	515-525	2013
Kita Y., Hashimoto S., Nakajima T., Nakatani H., Nishimatsu S., Nishida Y., Kanamaru N., Kaneda Y., Takamori Y, McMurray D., Tan EV., Cang ML., Saunderson P., Cruz ECD. Okada M.	Novel therapeutic vaccines [(Hsp65+IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy.	Hum Vaccines and Immunotherapeutics	9(3)	526-533	2013
Hijikata M, Shojima J, Matsushita I, Tokunaga K, Ohashi J, Hang NT, Horie T, Sakurada S, Hoang NP, Thuong PH, Lien LT, Keicho N.	Association of IFNGR2 gene polymorphisms with pulmonary tuberculosis among the Vietnamese.	Hum Genetic	131 (5)	675-682	2012
Keicho N, Matsushita I, Tanaka T, Shimbo T, Hang NT, Sakurada S, Kobayashi N, Hijikata M, Thuong PH, Lien LT	Circulating levels of adiponectin, leptin, fetuin-A and retinol-binding protein in patients with tuberculosis: markers of metabolism and inflammation	PLoS One	7 (6)	529-536	2012
Kobayashi K, Yuliwulandari R, Yanai H, Nakai I, Lien LT, Hang NT, Hijikata M, Keicho N, Tokunaga K	Association of TLR polymorphisms with development of tuberculosis in Indonesian females	Tissue Antigens	79 (3)	190-197	2012
Sakurada S, Hang NT, Ishizuka N, Toyota E, Hung LD, Chuc PT, Lien LT, Thuong PH, Bich PT, Keicho N, Kobayashi N	Inter-rater agreement in the assessment of abnormal chest X-ray findings for tuberculosis between two Asian countries	BMC Infectious Diseases	12 (1)	31	2012
Sapkota BR, Hijikata M, Matsushita I, Tanaka G, Ieki R, Kobayashi N, Toyota E, Nagai H, Kurashima A, Tokunaga K, Keicho N	Association of SLC11A1 (NRAMP1) polymorphisms with pulmonary Mycobacterium avium complex (MAC) infection	Hum immunol	73 (5)	529-536	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tomotada Iwamoto, Louis Grandjean, Kentaro Arikawa, Noriko Nakanishi, Luz Caviedes, Jorge Coronel, Patricia Sheen, Takayuki Wada, Carmen A. Taype, Marie-Anne Shaw, David A.J. Moore, and Robert H. Gilman.	Genetic diversity and transmission characteristics of Beijing family strains of <i>Mycobacterium tuberculosis</i> in Peru	PLoS ONE	7 (11)	e49651	2012
Noriko Nakanishi, Takayuki Wada, Kentaro Arikawa, Julie Millet, Nalin Rastogi, and Tomotada Iwamoto.	Evolutionary robust SNPs reveal the misclassification of <i>Mycobacterium tuberculosis</i> Beijing family strains into sublineages	Infection, Genetics and Evolution	16	174-177	2013
山田博之 他	Non-acid-fastness in <i>Mycobacterium tuberculosis</i> $\Delta kasB$ mutant correlates with the cell envelope electron density.	Tuberculosis	92	351-357	2012
御手洗聡 他	TRICORE, a novel bead-based specimen concentration method for the culturing of <i>Mycobacterium tuberculosis</i> .	Journal of Microbiological Methods	90	152-155	2012
近松絹代 他	GenoType® MTBDRslによる結核菌のfluoroquinolone, aminoglycosideおよびethambutol感受性検査に関する精度評価	結核	87	641-647	2012
青野昭男 他	抗酸菌塗抹検査外部精度評価の試み	日本臨床微生物学雑誌	22	279-283	2012

IV 研究成果の刊行物・別刷(一部)

The study of novel DNA vaccines against tuberculosis

Induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis

Masaji Okada,^{1,*} Yoko Kita,¹ Toshihiro Nakajima,² Satomi Hashimoto,¹ Hitoshi Nakatani,¹ Shiho Nishimatsu,¹ Yasuko Nishida,¹ Noriko Kanamaru,¹ Yasuhumi Kaneda,³ Yasushi Takamori,⁴ David McMurray,⁵ Esterlina V. Tan,⁶ Marjorie L. Cang,⁶ Paul Saunderson⁶ and E.C. Dela Cruz⁶

¹Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan; ²Ikeda Laboratory; Genomidea, Inc.; Midorigaoka, Ikeda; ³Division of Gene Therapy Science; Graduate School of Medicine; Osaka University; Suita, Osaka Japan; ⁴Department of Periodontology; Tsurumi University School of Dental Medicine; Tsurumi, Tsurumiku Japan; ⁵System Health Center; College of Medicine; Texas A&M University; College Station, TX USA; ⁶Leonard Wood Memorial Institute; Cebu, Philippines

Keywords: tuberculosis, vaccines against tuberculosis, CTL, monkeys, mice, HVJ-Envelope, HSP65 DNA+IL-12 DNA Vaccine, granulysin vaccine, Ksp37

Abbreviations: CTL, cytotoxic T cell; Ksp37, Killer-specific secretory protein of 37kDa; 15K granulysin, 15 kilodalton granulysin; HVJ, hemagglutinating virus of Japan; MDR-TB, multi-drug resistant tuberculosis; TB, *Mycobacterium Tuberculosis*

Results: HSP65 + IL-12 DNA vaccine showed higher protective efficacy compared with BCG in both mouse and monkey models of TB. It induced the TB-specific CTL in the mouse model of TB, while little level of activity was observed after the injection of BCG. It also showed strong therapeutic efficacy against MDR-TB. In the monkey model, the vaccine augmented the production of IFN- γ and IL-2 from PBL and the therapeutic effect was correlated with the level of IL-2. We next evaluated the potential of DNA vaccine encoding a granulysin, which is an important defensive molecule expressed by human T cells. We found that granulysin-encoding vaccine induced the differentiation of the CTL in vitro and in vivo. It also showed therapeutic efficacy against TB in the monkey as well as the mouse model. The DNA vaccine encoding a Ksp37 also induced the TB-specific CTL in vitro and in vivo in the mouse model. It augmented the production of IL-2, IFN- γ and IL-6 from T cells and spleen cells. A synergistic effect on the activation of the TB-specific CTL was observed by the combination of Ksp37 DNA vaccine with granulysin DNA vaccine.

Purpose and Methods: Emergence of the multi-drug resistant (MDR) *Mycobacterium tuberculosis* (TB) is a big problem in the world. We have developed novel TB vaccines [DNA vaccines encoding HSP65 + IL-12, granulysin or killer-specific secretory protein of 37kDa (Ksp37)] using Hemagglutinating virus of Japan -envelope (HVJ-E). It is suggested that the activity of the TB-specific CTL is one of the most important factor for the resistance to TB and immunity for TB in chronic human TB disease. Therefore, we examined the level of activation of the TB-specific CTL after the administration of these vaccines.

Conclusion: These data indicate that our novel vaccines (HSP65 + IL-12 DNA, granulysin and Ksp37) have a capability to activate the TB-specific CTL and will be very strong protective and therapeutic vaccines against TB.

Introduction

Tuberculosis is a major global threat to human health, with about 2 million people dying every year from *Mycobacterium tuberculosis* (TB) infection. The only tuberculosis vaccine currently available is an attenuated strain of *Mycobacterium bovis* BCG (BCG), although its efficacy against adult TB disease remains controversial. Furthermore, multi-drug resistant tuberculosis (MDR-TB) and extremely drug resistant TB (XDR-TB) are

becoming big problems in the world. It has been reported that a cytotoxic T-lymphocyte (CTL) is activated during the induction of host protective immune responses to TB.¹⁻⁴ In such circumstances, the development of therapeutic vaccine against TB as well as prophylactic vaccine against TB is expected. Therefore, we have recently developed a novel TB vaccine, a DNA vaccine expressing mycobacterial heat shock protein 65 (HSP65) and interleukin-12 (IL-12) delivered by the hemagglutinating virus of Japan (HVJ)-liposome (HSP65 + IL-12/HVJ). This vaccine

*Correspondence to: Masaji Okada; Email: okm@kch.hosp.go.jp
Submitted: 10/10/12; Accepted: 10/24/12
<http://dx.doi.org/10.4161/hv.23229>




Figure 1. HVJ-Envelope exerts strong adjuvant activity by the induction of CTL/NK and repression of regulatory T cells via the activation of dendritic cells.

was 100 fold more efficient than BCG in the murine model on the basis of the elimination of *M. tuberculosis*, which is mediated by the induction of CTL.^{1,5,6} Furthermore, the HSP65 + IL-12 vaccine delivered by HVJ-envelope was 10,000 fold more efficient than BCG in the murine TB-prophylactic model. This vaccine induced a strong activity of CTL against TB, while BCG vaccine induced little activity of CTL in the same model. It is considered that CTL is most important lymphoid cells for the immunity to TB in chronic human TB diseases. In the present study, we analyzed CTL activity and IFN- γ production after the vaccination with our vaccines. We also evaluated the prophylactic effect in the cynomolgus monkey and mouse models of TB. A nonhuman primate model of TB is an excellent model of human tuberculosis and provides a lot of information for vaccine development. In fact, we previously evaluated the protective effects of HSP65 + IL-12/HVJ vaccine in the cynomolgus monkey model and obtained a data indicating the synergistic effect of the HSP65 + IL-12/HVJ and BCG injected by a prime-boost method.^{3,7} The combination of the two vaccines showed a strong prophylactic efficacy in the monkey model infected with *M. tuberculosis* (100% survival). We have previously obtained a similar data in the monkey model of TB.^{5,6,8} In the present study, we examined the production of cytokines (IFN- γ and IL-2) from PBL and revealed the correlation of cytokine levels and efficacy in the monkey model of TB. We also compared the production levels of these cytokines between the combinatorial vaccination

(BCG prime and HSP65+IL12/HVJ vaccine boost) group and BCG vaccination group. We also evaluated the potential of other novel vaccines (DNA vaccines encoding granulysin or Ksp37), which were expected to induce the differentiation of CTL against TB. Granulysin is a protein secreted from T cells and NK cells and has an antibacterial effect on TB. Killer-specific secretory protein of 37 kDa (Ksp37) vaccine also showed anti-TB efficacy mediated by the induction of CTL. Synergistic effect on the activation of CTL in vitro was observed by the simultaneous administration of Ksp37- and granulysin-based vaccines. In the present study, we further demonstrated the correlation of the activation of CTL and the efficacy of these novel vaccines (HSP65 + IL-12/HVJ-E DNA vaccine, granulysin vaccine and Ksp37 vaccine) in the mouse and monkey models.

Results

Induction of CTL by HSP 65+IL-12/HVJ DNA vaccine in the mouse model of TB. The advantage of HVJ-Envelope vector is shown in **Figure 1**. (1) HVJ-Envelope is efficient delivery system and functions as an adjuvant for DNA vaccine, (2) It induces CTL and NK cell, (3) It induces a production of IL-6 which suppresses the regulatory T cell (T reg) and (4) It activates the innate immunity by the stimulation of RIG-I signaling pathway.

Mice were immunized three times with the DNA vaccine using HVJ-Envelope every three weeks. Four weeks after last

immunization, H37Rv *M.tuberculosis* (*M.tb*) was challenged. Five weeks after the challenge of *M.tb*, mice were sacrificed and C.F.U. of *M.tb* in lung, liver and spleen were accessed as reported previously.^{2,9-11} The C.F.U. of lungs in BCG vaccine alone group was decreased in 1 log compared with non-vaccinated mice group. The combination of the DNA vaccine (HSP65 DNA + IL-12) and BCG using prime-boost method enhanced the prophylactic efficacy (more than ten thousand fold) in the mouse model of TB (BCG prime-DNA vaccine boost). This regimen (BCG-prime then DNA vaccine boost) strongly increased the number of IFN- γ producing cells as compared with BCG vaccine alone (Table 1).

CD8⁺ CTLs have been considered as critical effectors of protective immunity to *M. tuberculosis*. This vaccine induced CD8⁺ CTL against TB, whereas a little or no CTL response was observed in either the naive or BCG-vaccinated mice (Figs. 2 and 3). We used HSP65 DNA-transfected syngenic tumor cells as target cells for CTL. This vaccine augmented the induction of CD8⁺ CD4⁻ CTL against target cells in vivo. On the other hand, a little or no CTL response was observed in BCG-vaccinated mice (Figs. 2 and 3).

Furthermore, we revealed that CD8⁺ T cells as well as CD4⁺ T cells were necessary for the prophylactic efficacy of this vaccine. The administration of anti-CD8 antibody or anti-CD4 antibody during the whole immunization period decreased the antibacterial immunity against TB and increased the number of C.F.U in lungs (Table 2). Simultaneous administration of anti-CD8 and anti-CD4 antibodies resulted in the further increase of the number of C.F.U in lungs (Table 2).

T cell activation by HSP 65+IL-12/HVJ DNA vaccine in the monkey model of TB. We used cynomolgus monkeys and prime-boost methods for the evaluation of our vaccines. We immunized monkeys with BCG Tokyo as a prime vaccine, and then immunize them with this vaccine as a boost vaccine. Survival rate of monkeys vaccinated with BCG prime-HSP65+IL-12 DNA boost was 100%. In contrast, survival rate of monkeys vaccinated with BCG alone was 33%. Thus, prime-boost method showed stronger efficacy than the method vaccinated with BCG alone (data not shown).

IFN- γ production from PBL was the highest level in the monkey group immunized with BCG prime-HSP65+IL-12/HVJ DNA vaccine boost (Fig. 4A). The strongest production of IL-2 from PBL was also observed in same group (Fig. 4B). Thus, in monkey as well as in mouse, we demonstrated that the combination of BCG Tokyo as a prime vaccine and the DNA vaccine as a boost vaccine is suitable method to get the prophylactic efficacies against TB. The prime-boost method efficiently induced the TB-specific CTL and also induced the production of IFN- γ and IL-2.

In Japan, BCG Tokyo vaccine is immunized in all infants. Thus it is expected to function as a prime vaccine. Therefore, we need the administration of novel vaccines (boost vaccines) for adults in Japan. We plan to use similar prime-boost method (BCG prime-DNA vaccine boost) in future clinical trial.

Table 1. ELISPOT assay for IFN- γ antigen-specific responses in the spleens of vaccinated mice following stimulation with HSP65 protein

Vaccination	(1 st /2 nd /3 rd)	Number of IFN- γ secreting cells/		
		(10 ⁶ splenocytes)		
G1	-/-	3	±	1
G2	-/-/BCG	13	±	6
G3	DNA*/DNA/DNA	16	±	4
G4	BCG/DNA/DNA	115	±	12

*DNA means HVJ-Envelope/HSP65 DNA+IL-12 DNA vaccine. Spleen cell cultures were stimulated with rHSP65 protein for 20 h. The number of IFN- γ -secreting cells specific for rHSP65 protein per million cells was determined individually by ELISPOT assay. Results are expressed as the mean \pm S.D. of 6 wells of 3 mice per group. The statistically significant differences of the G1 (naïve) group compared with the G2 (BCG alone group), G3 (DNA / DNA / DNA) or G4 (BCG / DNA / DNA) were observed ($p < 0.01$). The statistically significant difference between G2 group and G4 was observed ($p < 0.01$). The statistically significant difference between G3 group and G4 was observed ($p < 0.01$).

Correlation of IL-2 production and the therapeutic efficacy of HSP65+IL-12/HVJ DNA vaccine in the monkey model of TB. This vaccine showed therapeutic efficacy against MDR-TB and XDR-TB as well as drug-sensitive TB in mice.^{9,11,12} Therefore, we confirmed the therapeutic efficacy of the DNA vaccine and T cell responses induced by the DNA vaccine in the monkey model of TB. To establish the model of TB, human TB (5×10^2 CFU) was intratracheally instilled in monkeys. After the TB infection, DNA vaccine was injected intramuscularly 9 times, three times a week. Therapeutic effect was evaluated on the basis of survival, ESR, body weight, immune responses, chest X-ray and PPD skin test.

Injection of the therapeutic vaccine improved the survival of monkeys, as compared with the saline (control) group. No death was observed in monkey group treated with HSP65 +IL-12/HVJ DNA vaccine. In contrast, the survival rate of control saline group was 60% (data not shown). The proliferation of PBL after the stimulation with HSP65 was measured to evaluate the immune response. The proliferation of PBL from the monkeys treated with the DNA vaccine was more augmented than that from the monkeys treated with saline (data not shown). IL-2 production from PBL after the stimulation with killed TB H37Ra antigens was also examined. The level of IL-2 was higher in the DNA vaccine-treated group than that in saline control group (Table 3A). In addition, the IL-2 production from PBL after the stimulation with PPD was seemed to correlate with the survival after TB challenge. The level of IL-2 production of died monkeys was significantly lower than that of survived monkeys in saline group at 53days after TB challenge (Table 3B). IL-2 production by the stimulation with HSP65 protein was also extremely low level in died monkeys (data not shown). These data suggested that therapeutic efficacy of this vaccine correlate with the level of IL-2 production.

Induction of CTL by 15K granulysin vaccine. Granulysin is protein especially abundant in CTL and NK cells. It is classified into two major protein products [15kDa (15K) granulysin and 9kDa (9K) granulysin]. Latter granulysin (9K) exhibits




Figure 2. Induction of CD8⁺ CTL specific for HSP65 protein and *M. tuberculosis* by vaccination with HVJ-Envelope/HSP65 DNA+IL-12 DNA. Spleen cells from the naïve, BCG-, and HVJ-Envelope/HSP65 DNA+IL-12 DNA vaccinated mice were obtained eight weeks after the final vaccination. Cytotoxicity was assayed as release of radioactivity from ⁵¹Cr-labeled P815 target that had been transfected with HSP65 DNA using conventional ⁵¹Cr release assay as described in Materials and Methods.

potent cytotoxic activity against a broad panel of microbial targets, including bacteria, fungi and parasites. Granulysin is present in human CD8⁺ (and some CD4⁺) CTLs, NK cells, NKT cells and γ/δ T cells. However, the precise function of 15K granulysin has not yet been elucidated. We found that 15K granulysin was secreted from CD8 positive CTL, could enter into human macrophages and killed *M. tuberculosis* in the cytoplasm of macrophages. Expression of 15K granulysin protein and mRNA in CD8 positive T cells in the patients with Tuberculosis was significantly lower than those in the healthy volunteers. Moreover, the induction of 15K granulysin production after the stimulation with PPD antigen was suppressed in the supernatants of PBL from TB patients (data not shown).

Recombinant 15K granulysin protein enhanced the *in vitro* induction of human CTL in the MLC culture (Table 4A). *In vivo* induction of CTL in the spleen was augmented by the administration of recombinant 15K granulysin into C57BL/6 mice (Table 4B). The administration of recombinant 15K granulysin also augmented *in vivo* induction of CTL in the lymph node and PEC (peritoneal exudate cells) (Table 4B).

Synergistic effect was observed by the combination of recombinant 15K granulysin and IL-6-related DNA vaccine (IL-6+IL-6 receptor + gp130 DNA vaccine). *In vivo* induction of CTL specific for HSP65 TB antigen was augmented by the combination of two vaccines (data not shown). Two types of granulysin vaccines (recombinant 15K granulysin and 15K granulysin DNA vaccine) showed strong therapeutic efficacy in the mice infected with TB by aerosol challenge, resulted in the decrease of the number of C.F.U. in the lungs, liver and spleen (data not shown).

The granulysin (15K) has function as a CTL differentiation factor (Fig. 5). It augmented the differentiation of CTL from

precursor CTL into effector CTL. Thus, this is a first report that reveals the novel function of 15K granulysin (inducer of CTL differentiation). Effector CTLs produce 15K granulysin which induces the differentiation of CTL. Thus, there is a positive feedback loop (or autocrine system) in the regulation of the production of 15K granulysin. Granulysin (15K) might efficiently induce TB-specific CTL and enhance its therapeutic effect against TB infection by means of such a positive feedback loop system (Fig. 5).

CTL induction by Ksp37 vaccine. To investigate the immune function of Ksp37 protein, *in vitro* CTL induction by the addition of recombinant Ksp37 protein was analyzed in murine system. Splenic T cells from C57BL/6 were cultured with alloantigen (BALB/c spleen cells) in the presence or absence of recombinant Ksp37 for five days.

Induction of *in vitro* CTL differentiation was observed by the addition of recombinant Ksp37 (Fig. 6), suggesting that Ksp37 has function as a CTL differentiation factor.

IL-2 production from T cells and spleen cells was augmented by the addition of Ksp37 protein (Fig. 7A). Ksp37 also augmented the production of IFN- γ and IL-6 from murine spleen cells *in vitro* (Fig. 7B and C). Thus, Ksp37 is an inducer of multiple types of cytokines (IFN- γ , IL-2 and IL-6).

In order to study the immune function of Ksp37 *in vivo*, induction of CTL by the administration of Ksp37 DNA vaccine was investigated in murine system. Augmentation of CTL differentiation *in vivo* in the PEC was observed by the treatment with Ksp37 DNA vaccine (Fig. 8). Thus, Ksp37 DNA vaccine functioned as an inducer of CTL *in vivo* as well as *in vitro*. Furthermore, synergistic effect on the *in vitro* CTL induction was observed by the simultaneous treatment of Ksp37 and granulysin vaccines (Fig. 9).

Taken together, we established three kinds of novel vaccines and examined their potential in the mouse and monkey models *in vitro* and *in vivo*.

We demonstrated that: (1) HSP65+IL-12/HVJ-E DNA vaccine (HSP65 vaccine) had a prophylactic effect against TB. We revealed the induction of CD8⁺ CTL and CD4⁺ T cell were required for the protective efficacy of HSP65 vaccine. We also confirmed currently available vaccine (BCG vaccine) induced a little or no TB-specific CTL; (2) We also revealed the 15K granulysin functioned as a cytotoxic T cell differentiation factor (CTL differentiation factor). The production of granulysin is regulated by the positive feedback system. Thus, granulysin-based vaccine might have a strong therapeutic potency against TB, since it is expected to effectively induce TB-specific CTL;




Figure 3. Induction of CD8 positive CTL against TB by HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine, and differentiation of CTL.

(3) We also revealed that Ksp37 acts as a CTL differentiation factor in human and mouse. Ksp37 vaccine augmented the production of IL-2, IFN- γ , and IL-6 from murine T cells and spleen cells; (4) We also demonstrated the synergy of the vaccines, e.g., synergistic effect on the in vitro CTL induction was shown by the combination of Ksp37 and granulysin DNA vaccines.

These data indicate that all of our novel vaccines are able to induce the TB-specific CTL effectively and the combination regimen of those vaccines might provide the new strategy to get very strong protective and therapeutic efficacy against TB.

Discussion

In the present study, we studied the CTL differentiation against TB induced by the administration of novel vaccines (HSP65+IL-12/HVJ-E DNA vaccine, granulysin vaccine and Ksp37 vaccine). We found (1) 15K granulysin functions as a cytotoxic T cell differentiation factor (CTL differentiation factor). The therapeutic efficacy of 15K granulysin vaccine might be mediated by the induction CTL; (2) Ksp37 also acts as a CTL differentiation factor in mice; (3) Ksp37 vaccine induces the production of IL-2, IFN- γ and IL-6 from murine T cells and spleen cells; (4) Synergistic effect on the in vitro CTL induction is expected by the combination of Ksp37 vaccine and granulysin vaccine.

On the other hand, it was demonstrated that HSP65 +IL-12/HVJ-E DNA vaccine (HSP65 vaccine) has a prophylactic efficacy against TB and that the induction of CTL specific for TB is important for the efficacy of the vaccine. By using CD8 antibody and CD4 antibody we found CD8 positive CTL and CD4 positive T cell were required for the protective efficacy of HSP65

Table 2. The in vivo necessity CD8 positive T cells and CD4 positive T cells for prophylactic efficacy of the HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine

	Vaccination			Antibody	Log ₁₀ CFU of TB in the lung
	1 st	2 nd	3 rd		
G1	-	-	-	-	6.6 ± 0.3
G2	BCG	DNA	DNA	-	5.3 ± 0.3
G3	BCG	DNA	DNA	α CD8 Ab	5.9 ± 0.1
G4	BCG	DNA	DNA	α CD4 Ab	7.1 ± 0.5
G5	BCG	DNA	DNA	α CD8 Ab+ α CD4 Ab	8.4 ± 0.2

*p < 0.05 G2vsG3, G4; **p < 0.01. G2vsG5, Anti-CD8 antibody and/or Anti-CD4 antibody were injected i.p. every 5 d after the challenge of TB. BCG was used as a prime vaccine and the DNA vaccine was immunized twice (HVJ-Envelope/HSP65 DNA 50 μ g + IL-12 DNA50 μ g) as boost vaccine. Four weeks after last immunization, 5 × 10⁵ H37Rv were challenged i.v. into mice. (G2-G3: p < 0.05); (G2-G4: p < 0.05); (G2-G5: p < 0.01).

vaccine in vitro and in vivo. In contrast, BCG vaccine induced a little or no CTL against TB.

There are increasing evidences which indicate the importance of cytotoxic cells.^{3,4} Their role in immunity to TB has been revealed by using knockout mice lacking a gene or genes related to major histocompatibility complex (MHC) class I (e.g., transporter associated with antigen processing-1, CD8, 2m, and MHC class I heavy chain). These genes are involved in the antigen presentation via MHC class I, by cell-transfer experiments and by depletion of CD8⁺ CTLs with antibodies. CD8⁺ CTLs play a major role in the control of the latent TB.^{1,4,6}




Figure 4. IFN- γ and IL-2 production efficacy of HSP65+IL-12/HVJ and BCG using prime-boost method against TB challenged cynomolgus monkeys. Group of animals were vaccinated three times (every three weeks) with (1^o) BCG Tokyo, (2^o) HSP65 +IL-12/HVJ, (3^o) HSP65+IL-12/HVJ = G1(■) BCG prime-HVJ/DNA boost group; (1^o) HSP65+IL-12/HVJ, (2^o) HSP65 +IL-12/HVJ, (3^o) BCG = G2(□) HVJ/DNA prime-BCG boost group; (1^o) HSP65+IL-12/HVJ, (2^o) HSP65 +IL-12/HVJ, (3^o) HSP65+IL-12/HVJ = G3(▨); (1) BCG, (2^o) saline, (3^o) saline = G4(▩) G4 group animals were vaccinated with BCG once; (1^o) saline, (2^o) saline, (3^o) saline = G5(▪). (A) PBL from vaccinated monkeys on 56 d or 112 d after 1st immunization, were cultured for three days. IFN- γ activity on 56 d and IL-2 activity (B) on 112 days were assessed by ELISA.

The CTLs other than CD8⁺ cells might be even more important in humans. It has been reported that there are additional effector modalities, such as granulysin, that are able to kill *M. tuberculosis*.¹² Lymphocyte subsets that recognize antigens presented by molecules other than MHC class I were also reported to be involved in the immunity against TB. In addition to MHC class I molecule, these lymphocytes are able to utilize HLA-E or group I CD1 molecules (CD1a, CD1b, etc.) for the recognition of antigens.^{6,13,14}

The precise function of 15K granulysin has not yet been elucidated.¹⁵ We found that 15K granulysin was secreted from CD8 positive CTL and entered into human macrophages followed by the killing of *M. tuberculosis* in the cytoplasm.^{10,11} The expression levels of 15K granulysin protein and mRNA in CD8 positive T cells of the patients with drug sensitive TB were lower than that of the healthy volunteers. Among the TB patients, the expression level of 15K granulysin protein in CD8 positive T cells of the patients with multi-drug resistant tuberculosis (MDR-TB) was significantly lower than that in the patients with drug-sensitive TB. The expressions of 15K granulysin after the stimulation with PHA-P, ConA, alloantigens or PPD antigens were significantly suppressed in the supernatants of PBL from MDR-TB patients.^{10,11} We have currently established 15K granulysin transgenic mice and 9K granulysin transgenic mice.¹¹ It was demonstrated that 15K granulysin transgenic mice as well as 9K granulysin transgenic mice were resistant to TB infection. The number of TB (C.F.U. in tissues) was decreased in those transgenic mice. As to the induction of anti-TB immunity, differentiation and proliferation of TB-specific CTL was augmented in those transgenic mice. In addition, enhanced production of cytokines was observed.

In the present study, we demonstrated that 15K granulysin has function as a CTL differentiation factor. Granulysin (15K) augmented the differentiation of CTL from precursor CTL into effector CTL. It has been reported that 15K granulysin is produced from effector CTL. Thus, it is suggested that the production of 15K granulysin is regulated by positive feedback loop system. Large amount of granulysin might enhance the induction of CTL resulting in the increase of the therapeutic efficacy. Recently, it was reported that 15K granulysin activated antigen-presenting cells (APC, dendritic cells or macrophages) and augmented the production of several cytokines.^{16,17} Therefore, 15K granulysin is able to activate the immune system effectively, since the target cell of it is both APC and CTL.

Vaccination with BCG prime-HSP65 + IL-12/HVJ boost showed better protective efficacy than BCG alone on the basis of the ESR, chest X-ray findings and immune responses. Importantly, treatment with HSP65 + IL-12/HVJ resulted in an increased survival for over a year.⁵

Significantly higher levels of cytokine production from PBL (IFN- γ and IL-2) were observed in prime (BCG) - boost (HSP65 vaccine) group than those in BCG vaccine group. Prime-boost method was reported in the study of MVA85A vaccine, which is a modified vaccine virus Ankara (MVA) strain expressing antigen 85A. In phase I clinical studies, this vaccine has induced high immune responses in previously BCG-vaccinated individuals.¹⁸

Table 3. IL-2 production from PBL in the cynomolgus monkeys

(A)	(monkeys)	Responder cell	H37Ra Ag	IL-2 (u/ml)
		vaccine-treated	(-)	2 \pm 3
		control	(-)	0 \pm 0
		vaccine-treated	(+)	13 \pm 4
		control	(+)	3 \pm 5
(B)	G4 (saline control)	IL-2 production (U/ml) (HSP65 stimulation)		Survival
	ID of monkeys	Baseline	Day53 Post-challenge	
	PR 6847 D	0.0	21.1	Survival
	PR 8018 B	0.0	43.2	Survival
	PR 5368 B	0.0	43.2	Survival
	PR PbB2-4F	0.0	0.0	Death (after 41 d)
	PrZ7-51 AC	0.0	0.0	Death (after 55 d)

(A) Augmentation of IL-2 production from PBL by H37Ra stimulation in the monkeys treated with HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine. (B) IL-2 production from PBL in the survived monkeys and the non-survived monkeys. PBL from monkeys on day 53 after TB challenge were stimulated with HSP65 protein for 3 d. ID (PR PbB2-4F) monkey and ID (PrZ7-51 AC) were died after 41 d and 55 d, respectively.

Table 4. In vitro and in vivo CTL induction by 15K granulysin

(A)	In vitro (5day MLC)	15K Granulysin	% Specific Cytotoxicity	
		-	8.0	\pm 1.0
		+	23.0	\pm 0.5
(B)	In vivo CTL			
	spleen	-	1.0	\pm 0.2
		+	11.0	\pm 0.3
	LN	-	7.2	\pm 2.5
		+	22.5	\pm 2.8
	PEC	-	0.5	\pm 2.0
		+	28.5	\pm 1.0

(A) In vitro induction of human cytotoxic T cell by the stimulation with recombinant 15K granulysin protein. T cells from human PBL were obtained by nylon-wool column method. An amount of 1×10^6 T cells were cultured with CESS_{MMC} cells (Mitomycin C treated CESS tumor cells) in the presence of 15K granulysin for five days. CTL activity of effector cells was assayed using ⁵¹Cr-labelled CESS cells. Results are expressed as % Specific cytotoxicity \pm S.D. (B) In vivo induction of CTL by 15K granulysin. C57BL/6 were injected i.p. with 1×10^7 syngeneic FBL-3 tumor cells and then treated with recombinant 15K granulysin i.p. (5 μ g/mouse) six times. Twenty-one days after FBL-3 inoculation, mice were sacrificed, and spleen cells, lymph node (LN) cells and peritoneal exudates cells (PEC) were used as effector cells for CTL. Cytotoxic activity against FBL-3 cells were assessed using ⁵¹Cr release method.

Boosting of BCG vaccination with MVA85A reduced the expression of immunoregulatory cytokine TGF- β .¹⁹ Aeras-402 DNA (DNA that expressed 85A, 85B and TB10.4) vaccine is a recombinant adenovirus vector-based vaccine and expected as




Figure 5. Differentiation of CTL by 15K granulysin and positive feedback loop of 15K granulysin in CTL induction. Precursor CTL are activated by IL-2 in the early stage of CTL induction of five day MLC. On the other hand, IL-6 acts, as a cytotoxic T cell differentiation factor, on the late stage of CTL induction as shown by Okada, et al. (J.I. 1988). 15K granulysin is produced from effector CTL, and induced the differentiation of CTL as a CTL differentiation factor. (Positive feedback loop by 15K granulysin).




Figure 6. Induction of CTL differentiation by killer-specific secretory protein of 37kd (Ksp37). Splenic T cell from C57BL/6 mice (H-2^b) were obtained as described in (PNAS Okada et al. 1981), and cultured with uv-treated BALB/c (H-2^d) spleen cells (Mitomycin C treated) in the presence of 100ng/ml rKsp37 and/or an anti-Ksp37 antibody for 5 d. CTL activity against P815 tumor cells (H-2^d) was assessed by using ⁵¹Cr assay.

a boosting vaccine for BCG-primed individuals.⁶ Several other vaccines use a prime-boost strategy to enhance the immune responses.²⁰ Recently, Rahman et al. established a plasmid-based vaccine (rBCG/rAd35 vaccine) which enhanced the activation of MHC class I-restricted CD8⁺ cytotoxic T cell. It is a recombinant BCG (rBCG) expressing a pore-forming toxin and TB antigens (Ag85A, 85B and TB10.4). A non-replicating adenovirus35

encoding the same TB antigens (rAd35) is used as a boost vaccine. The prime-boost method using rBCG and rAd35 vaccines were evaluated in nonhuman primate model.²¹ Similar to our BCG prime- HSP65 + IL-12 DNA boost method, the results suggested that activation of CD8⁺ effector CTL followed by the production of granulysin at the local site were involved in the protective effects of this vaccine (prime-boost). Thus, induction of TB-specific CTL and the augmentation of the cytokine production (IFN- γ , IL-2) might be a critical factor to obtain the prophylactic efficacy.

Furthermore, we established other vaccines (granulysin vaccine and Ksp37 vaccine) which induced the differentiation of CTL against TB. The granulysin secreted from T cells and NK cells has a therapeutic effect against TB.

On the other hand, Ksp37 is expressed selectively in the effector subset of CD8⁺T cells, CD16⁺ NK cells and γ/δ T cells.²² Expression of Ksp37 mRNA was closely correlated with good prognosis of ovarian cancer and gliomas.²³ However, immunological function(s) of Ksp37 is still unclear. Ksp37 showed anti-TB effects by the induction of CTL in the present study. We demonstrated that Ksp37 vaccine also induced murine CTL both in vitro and in vivo. Ksp37 vaccine augmented the production of IL-2, IFN- γ and IL-6 from murine T cells and spleen cells. Synergistic effect on the in vitro CTL induction was observed by the combination of Ksp37 and granulysin vaccines. We also demonstrated the correlation between the activity of CTL induction/cytokine production and the efficacy of these vaccines in the mouse and monkey models.

In conclusion, our data might provide novel strategy to obtain strong protective and therapeutic efficacy. The important factors are the induction of CTL and production of several kinds of cytokines. In addition, the combination of several kinds of vaccines will enhance the efficacy of vaccines, which will be necessary for the vaccine for the severe TBs such as MDR-TB and XDR-TB. Similar to the treatment of cancers or infectious diseases, the regimen of combination therapy will provide useful rationale that is necessary to develop more effective vaccines against TB.

Materials and Methods

Bacteria. *M. tuberculosis* strains H37Rv and *M. bovis* BCG Tokyo, were kindly provided by Dr. I. Sugawara (JATA, Tokyo, Japan). *M. bovis* BCG Tokyo was maintained in synthetic Sauton's medium (Wako Chemicals, Osaka, Japan).¹

Animals. Inbred and specific pathogen-free female BALB/c mice and DBA/1 mice were purchased from Japan SLC (Shizuoka, Japan). Mice were maintained in isolator cages, manipulated in laminar flow hoods, and used between 8 and 10 weeks of age as described previously.¹

Plasmid construction. The *HSP65* gene was amplified from *M. tuberculosis* H37Rv genomic DNA, and cloned into pcDNA3.1 (+) (Invitrogen, San Diego, CA) to generate pcDNA-hsp65 (designated as HSP65 DNA) as described previously.¹ The *HSP65* gene was fused with mouse Ig κ secretion signal sequence, and pcDNA-Ighsp65 was generated. For construction of the mouse IL-12 (mIL-12) *p40* and *p35* single-chain genes, *mIL12p35* and

mIL12p40 genes were cloned from pcDNA-p40p35,¹ fused and cloned into pcDNA3.1 (+) to generate pcDNA-mIL12p40p35-F (designated as mIL-12 DNA).

HVJ-E vaccination. HVJ-E was prepared as described previously.¹ The HVJ-E complex was aliquoted and stored at -70°C until use. DNA vaccines encoding *M. tuberculosis* HSP65 and IL-12 were encapsulated into HVJ-Envelope or HVJ-liposomes.²⁴ HVJ-liposomes and HVJ-Envelope were prepared as described previously.²⁵⁻²⁹ Groups of BALB/c mice were vaccinated 3 times at 3-week intervals with 100 µL of HVJ-E solution containing 50 µg of pcDNA-IgHSP65 and 50 µg of mIL12 DNA.

Challenge infection of vaccinated animals and bacterial load determination. Mice were challenged by the intravenous route with 5×10^5 CFU of *M. tuberculosis* H37Rv 4 weeks after the third vaccination as described previously.¹

Methods for the evaluation of the prophylactic efficacy of the vaccine on the TB infection of the monkeys. Cynomolgus monkeys were housed in a BSL 3 animal facility of the Leonard Wood Memorial Research Center. The animals were vaccinated three times with the HVJ-envelope with expression plasmid of both HSP65 and human IL-12 (HSP65 + hIL-12/HVJ: 400 µg i.m.), and then challenged with the *M. tuberculosis* Erdman strain (5×10^2) by intratracheal instillation. Survival, immune responses (proliferation of PBL and cytokines production), body weight, ESR, PPD skin test and chest X-p findings were examined as described in our previous studies.^{5,6,8,9} All animal experiments were approved by the Leonard Wood Memorial Animal Care and Use Committee and the National Hospital Organization Kinki-chuo Chest Medical Center Animal Care and Use Committee.

Methods for the evaluation of the therapeutic efficacy of the vaccine on the *M. tuberculosis*-infected monkeys. Cynomolgus monkeys were vaccinated nine times with the HVJ-envelope with expression plasmid of both HSP65 and human IL-12 (HSP65 + hIL-12/HVJ: 400 µg i.m.), one week after the challenge with the *M. tuberculosis* Erdman strain (5×10^2) by intratracheal instillation. Immune responses and survival were examined as described in our previous studies.^{5,8,9}

Reagents and antibodies. Fetal calf serum (FCS: lot AGC6341) was obtained from Hyclone (Logan, UT). Anti-L3T4, anti-Lyt2.2 monoclonal antibodies and anti-Thy1.2 antibody were provided.^{1,2}

Cell lines. A mouse mastocytoma cell line (P815: DBA/2 origin) was kindly provided by Dr. C. S. Henney (Fred Hutchinson Cancer Res. Center, Seattle).¹ The P815 cells were maintained in RPMI 1640 medium (Flow Laboratories, Inc. Mclean, VA) supplemented with 10% FCS, penicillin (100 U/ml), streptomycin (100 µg/ml) and 5×10^{-5} M 2-mercaptoethanol.^{1,2}

Tuberculosis-specific cytotoxic test using ⁵¹Cr release. Eight weeks after the final vaccination, CTL activity of spleen cells and mesenteric lymph node cells from vaccinated mice was assessed by using the ⁵¹Cr-release assay. P815 mastocytoma cells, which have the same major histocompatibility complex (MHC) (H-2^d) as BALB/c mice, were transfected with pcDNA-hsp65 and used as HSP65 protein-expressing target cells. A total of 2×10^6 cells/ml effector splenic cells were treated with anti-CD8 antibody, anti-CD4 antibody or anti-Thy1.2 antibody followed




Figure 7. Augmentation of cytokines (IL-2, IFN- γ and IL-6) production by Ksp37 was also observed. (A) Augmentation of IL-2 production from T cells or spleen cells by Ksp37. An amount of 5×10^6 splenic T cells or spleen cells from C57BL/6 mice were cultured with 5×10^5 BALB/c spleen cells (Mitomycin-C treated) in the presence of rKsp37 for two days. IL-2, IFN- γ and IL-6 activities in the supernatants were assessed by ELISA. (B) Augmentation of IFN- γ production from spleen cells by Ksp37. (C) Augmentation of IL-6 production from spleen cells by Ksp37.




Figure 8. Augmentation of CTL differentiation in vivo by the treatment with Ksp37 DNA was demonstrated. C57BL/six mice were challenged with killed H37Ra antigen (1,000 μ g/mouse) in vivo (i.p.) and then treated with Ksp37 DNA (100 μ g/mouse, six times) i.m. Twenty-one days after challenge of killed TB antigen, and PEC (peritoneal exudate cells) from these mice were harvested. CTL activity against TB antigen (HSP65 antigen) was assessed by using ^{51}Cr EL-4 which had been transfected with HSP65 DNA.




Figure 9. Synergistic efficacy of Ksp37 and granulysin on the in vitro CTL induction. Splenic T cells were cultured with uv-treated BALB/c spleen cells (Mycotomycin C treated) in the presence or absence of 100ng/ml Ksp37 protein and 500ng/ml 15K granulysin protein for 5 d. Five days after culture, CTL activity against P815 tumor cells was assessed by using ^{51}Cr release assay.

by complement.¹ ^{51}Cr release was assessed using the ^{51}Cr -release assay^{10,30-34} at the Effector:Target (E:T) ratio of 50:1. Spontaneous lysis (with medium alone) and maximum lysis (^{51}Cr release after three cycles of freeze-thaw) were set up for background and targets. Percent specific lysis was determined as: [(experimental release – spontaneous release)/(maximum release – spontaneous release)] \times 100.³⁰⁻³⁴

Production of cytokines (IL-2 and IFN- γ). Mouse cytokines were measured in quantitative ELISAs for IL-2 and IFN- γ as described previously.^{1,2}

ELISPOT assay. The spleens were removed aseptically from vaccinated mice 3 weeks after the third vaccination. Antigen-specific IFN- γ -producing cells were determined by enzyme-linked immunosorbent spot (ELISPOT) as described previously.^{1,2}

Statistical analysis. Tukey-Kramer's HSD tests were used to compare \log_{10} value of CFU between groups following challenge and T cell responses between groups in ELISPOT assay. Student's t-tests were performed to compare T cell responses between groups in T cell proliferation assay and granuloma formation between groups following challenge. A *P*-value of < 0.05 was considered significant.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

This study was supported by a Health and Labour Science Research Grant from MHLW (H17-shinko-5, H20-Shinko-14, H23-Shinko-2), grants from Osaka Tuberculosis research foundation and Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science and Technology Japan.

References

- Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against *Mycobacterium tuberculosis* by T cell activation. *Vaccine* 2006; 24:1191-204; PMID:16216394; <http://dx.doi.org/10.1016/j.vaccine.2005.08.103>.
- Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis. *Clin Dev Immunol* 2011; 2011:549281; PMID:21437226; <http://dx.doi.org/10.1155/2011/549281>.
- Boom WH. New TB vaccines: is there a requirement for CD8 T cells? *J Clin Invest* 2007; 117:2092-4; PMID:17671648; <http://dx.doi.org/10.1172/JCI32933>.
- van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent *Mycobacterium tuberculosis* infection is dependent on CD8 T cells. *Eur J Immunol* 2000; 30:3689-98; PMID:11169412; [http://dx.doi.org/10.1002/1521-4141\(200012\)30:12<3689::AID-IMMU3689>3.0.CO;2-4](http://dx.doi.org/10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4).
- Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. *Vaccine* 2007; 25:2990-3; PMID:17280753; <http://dx.doi.org/10.1016/j.vaccine.2007.01.014>.
- Okada M, Kita Y. Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine. *Hum Vaccin* 2010; 6:297-308; PMID:20372079; <http://dx.doi.org/10.4161/hv.6.4.10172>.
- Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, et al. The Philippine cynomolgus monkey (*Macaca fascicularis*) provides a new nonhuman primate model of tuberculosis that resembles human disease. *Nat Med* 1996; 2:430-6; PMID:8597953; <http://dx.doi.org/10.1038/nm0496-430>.
- Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. *Vaccine* 2005; 23:2132-5; PMID:15755583; <http://dx.doi.org/10.1016/j.vaccine.2005.01.057>.

9. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic and therapeutic vaccine against tuberculosis. *Vaccine* 2009; 27:3267-70; PMID:19200841; <http://dx.doi.org/10.1016/j.vaccine.2009.01.064>.
10. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis. *Hum Vaccin* 2011; 7(Suppl):60-7; PMID:21546794; <http://dx.doi.org/10.4161/hv.7.0.14563>.
11. Kita Y, Okada M, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models. *Hum Vaccin* 2011; 7(Suppl):108-14; PMID:21263229; <http://dx.doi.org/10.4161/hv.7.0.14571>.
12. Stegelmann F, Bastian M, Swoboda K, Bhat R, Kiessler V, Krensky AM, et al. Coordinate expression of CC chemokine ligand 5, granulysin, and perforin in CD8⁺ T cells provides a host defense mechanism against *Mycobacterium tuberculosis*. *J Immunol* 2005; 175:7474-83; PMID:16301655.
13. Woodworth JS, Behar SM. *Mycobacterium tuberculosis*-specific CD8⁺ T cells and their role in immunity. *Crit Rev Immunol* 2006; 26:317-52; PMID:17073557; <http://dx.doi.org/10.1615/CritRevImmunol.v26.i4.30>.
14. Lewinsohn DM, Zhu L, Madison VJ, Dillon DC, Fling SP, Reed SG, et al. Classically restricted human CD8⁺ T lymphocytes derived from *Mycobacterium tuberculosis*-infected cells: definition of antigenic specificity. *J Immunol* 2001; 166:439-46; PMID:11123322.
15. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. *Science* 1998; 282:121-5; PMID:9756476; <http://dx.doi.org/10.1126/science.282.5386.121>.
16. Castiello L, Stroncek DF, Finn MW, Wang E, Marincola FM, Clayberger C, et al. 15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level. *J Transl Med* 2011; 9:41; PMID:21501511; <http://dx.doi.org/10.1186/1479-5876-9-41>.
17. Clayberger C, Finn MW, Wang T, Saini R, Wilson C, Barr VA, et al. 15 kDa granulysin causes differentiation of monocytes to dendritic cells but lacks cytotoxic activity. *J Immunol* 2012; 188:6119-26; PMID:22586033; <http://dx.doi.org/10.4049/jimmunol.1200570>.
18. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. *Nat Med* 2004; 10:1240-4; PMID:15502839; <http://dx.doi.org/10.1038/nm1128>.
19. Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whelan KT, Alder NC, et al. Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1. *Vaccine* 2008; 26:5269-75; PMID:18682270; <http://dx.doi.org/10.1016/j.vaccine.2008.07.040>.
20. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. *Lancet* 2010; 375:2110-9; PMID:20488515; [http://dx.doi.org/10.1016/S0140-6736\(10\)60393-5](http://dx.doi.org/10.1016/S0140-6736(10)60393-5).
21. Rahman S, Magalhaes I, Rahman J, Ahmed RK, Sizemore DR, Scanga CA, et al. Prime-boost vaccination with rBCG/rAd35 enhances CD8⁺ cytolytic T-cell responses in lesions from *Mycobacterium tuberculosis*-infected primates. *Mol Med* 2012; 18:647-58; PMID:22396020; <http://dx.doi.org/10.2119/molmed.2011.00222>.
22. Ogawa K, Tanaka K, Ishii A, Nakamura Y, Kondo S, Sugamura K, et al. A novel serum protein that is selectively produced by cytotoxic lymphocytes. *J Immunol* 2001; 166:6404-12; PMID:11342666.
23. Elgaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, et al. POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. *PLoS One* 2010; 5:e13837; PMID:21079801; <http://dx.doi.org/10.1371/journal.pone.0013837>.
24. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. *Hum Gene Ther* 1997; 8:2133-41; PMID:9414261; <http://dx.doi.org/10.1089/hum.1997.8.17-2133>.
25. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. *Mol Ther* 2002; 6:219-26; PMID:12161188; <http://dx.doi.org/10.1006/mthe.2002.0647>.
26. Kaneda Y. New vector innovation for drug delivery: development of fusogenic non-viral particles. *Curr Drug Targets* 2003; 4:599-602; PMID:14577648; <http://dx.doi.org/10.2174/1389450033490740>.
27. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. *Adv Genet* 2005; 53:307-32; PMID:16240999; [http://dx.doi.org/10.1016/S0065-2660\(05\)53012-8](http://dx.doi.org/10.1016/S0065-2660(05)53012-8).
28. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. *J Gene Med* 2005; 7:1044-52; PMID:15756713; <http://dx.doi.org/10.1002/jgm.753>.
29. Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. *Mol Cancer Ther* 2006; 5:1021-8; PMID:16648574; <http://dx.doi.org/10.1158/1535-7163.MCT-05-0352>.
30. Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. *Proc Natl Acad Sci U S A* 1981; 78:7717-21; PMID:6801660; <http://dx.doi.org/10.1073/pnas.78.12.7717>.
31. Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. *Cancer Res* 1997; 57:1335-43; PMID:9102222.
32. Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. *J Exp Med* 1983; 157:583-90; PMID:6600487; <http://dx.doi.org/10.1084/jem.157.2.583>.
33. Okada M, Klimpel GR, Kuppers RC, Henney CS. The differentiation of cytotoxic T cells in vitro. I. Amplifying factor(s) in the primary response is L_{yt} 1 + cell dependent. *J Immunol* 1979; 122:2527-33; PMID:156228.
34. Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. *J Exp Med* 1983; 157:583-90; PMID:6600487; <http://dx.doi.org/10.1084/jem.157.2.583>.

Novel therapeutic vaccines [(HSP65 + IL-12) DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy

Yoko Kita,¹ Satomi Hashimoto,¹ Toshihiro Nakajima,² Hitoshi Nakatani,¹ Shiho Nishimatsu,¹ Yasuko Nishida,¹ Noriko Kanamaru,¹ Yasuhumi Kaneda,³ Yasushi Takamori,⁴ David McMurray,⁵ Esterlina V. Tan,⁶ Marjorie L. Cang,⁶ Paul Saunderson,⁶ E.C. Dela Cruz⁶ and Masaji Okada^{1,*}

¹Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan; ²Ikeda Laboratory; GenomIdea Inc.; Midorigaoka, Ikeda; ³Division of Gene Therapy Science; Graduate School of Medicine; Osaka University; Suita, Osaka Japan; ⁴Department of Periodontology; Tsurumi University School of Dental Medicine; Tsurumi, Tsurumiku Japan; ⁵Texas A&M University; System Health Center; College of Medicine; College Station, TX USA; ⁶Leonard Wood Memorial Institute; Cebu, Philippines

Keywords: therapeutic vaccine against, tuberculosis, HSP65 DNA + IL-12 DNA vaccine, granulysin vaccine, Ksp37 vaccine, chemotherapy, Ksp37 transgenic mouse, synergistic therapeutic efficacy, MDR-TB, XDR-TB

Abbreviations: HVJ, hemagglutinating virus of Japan; 15K granulysin, 15 kilodalton granulysin; Ksp37, killer specific secretory protein of 37kDa; MDR-TB, multi-drug resistant tuberculosis; XDR-TB, extremely drug resistant tuberculosis; Tg, transgenic

Purpose: Multi-drug resistant tuberculosis (MDR-TB) and extremely drug resistant (XDR) TB are big problems in the world. We have developed novel TB therapeutic vaccines, HVJ-Envelope/HSP65 + IL-12 DNA vaccine (HSP65-vaccine), granulysin vaccine and killer specific secretory protein of 37kDa (Ksp37) vaccine.

Results and Methods: HSP65 vaccine showed strong therapeutic effect against both MDR-TB and XDR-TB in mice. Intradermal immunization of HSP65-vaccine showed stronger therapeutic effect against TB than intramuscular or subcutaneous immunization. Furthermore, the synergistic therapeutic effect was observed when the vaccine was administered in combination with Isoniazid (INH), which is a first line drug for chemotherapy. The combination of types of vaccines (HSP65- and granulysin- vaccines) also showed synergistic therapeutic effect. In the monkey model, granulysin-vaccine prolonged the survival period after the infection of TB and long-term survival was observed in vaccine-treated group. We examined the potential of two kinds of novel DNA vaccines (Ksp37-vaccine and granulysin-vaccine). Both vaccines augmented in vivo differentiation of CTL against TB. We measured the amount of Ksp37 protein in human serum and revealed that the level of Ksp37 protein of patients with tuberculosis was lower than that of healthy volunteers. Therefore, we established Ksp37 transgenic mice as well as granulysin transgenic mice to elucidate the function of those proteins. Both transgenic mice were resistant to TB infection.

Conclusion: These data indicate the potential of combinational therapy; the combination of two DNA vaccines or combination of DNA vaccine with antibiotic drug. Thus, it will provide a novel strategy for the treatment of MDR-TB.

Introduction

Tuberculosis is a major global threat to human health, with about 2 million people dying every year from Mycobacterium tuberculosis (TB) infection. The only tuberculosis vaccine currently available is an attenuated strain of Mycobacterium bovis BCG (BCG), although its efficacy against adult TB disease remains controversial. Furthermore, multi-drug resistant tuberculosis (MDR-TB) and extremely drug resistant TB (XDR-TB) are becoming big problems in the world. About 500,000 of people around the world are affected by MDR-TB every year. However,

there are a small number of effective drugs against MDR-TB. In such circumstances, the development of therapeutic as well as prophylactic vaccines against TB is required.

Cynomolgus monkey model is the best animal TB model to evaluate the potential of newly developed vaccines as reported by Walsh and Tan.¹ Onset and progress after TB infection in the cynomolgus monkey is very similar to human TB disease.¹⁻³ SCID-PBL/hu is an IL-2 receptor γ -chain disrupted mouse (NOD-SCID) transplanted with human PBL. It is an in vivo humanized immune model and provides a useful tool for investigating human immune responses to the administration

*Correspondence to: Masaji Okada; Email: okm@kch.hosp.go.jp
Submitted: 10/10/12; Accepted: 10/25/12
<http://dx.doi.org/10.4161/hv.23230>

Table 1. Therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine on TB infection in murine models

- 1. HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine showed therapeutic efficacy against MDR-TB as well as drug-sensitive TB in mice.**
- 2. Significant prolongation of survival was observed in the XDR-TB infected mice by the treatment with this vaccine.**
- 3. Therapeutic efficacy of this vaccine on chronic TB disease models using a mouse infected with TB in the aerosol chamber was demonstrated.**

Therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine was evaluated by using mouse models. Therapeutic efficacies of this vaccine on the MDR-TB infection and XDR-TB infection were observed.

of vaccines.^{4,5} Transgenic mice that express the components of vaccine also provide a lot of information about novel TB vaccines. Therefore, we used three animal models (cynomolgus monkey model of TB, SCID-PBL/hu mice and transgenic mice) to develop three kinds of novel vaccines against TB.

We have previously evaluated a novel therapeutic TB vaccine which consists of plasmid DNA encoding HSP65 + IL-12 and HVJ-Envelope (HSP65-vaccine) and revealed the efficacy of the vaccine in these animal models.⁶⁻⁹ However, it is very important to treat the patients with TB completely within a short period of time. Therefore, we improved the regimen of the vaccination. We first examined a combination therapy of vaccination and chemotherapy. In the present study, we used a HSP65-vaccine for the vaccination and first line TB drugs (INH or RFP) for the chemotherapy. We next identified a suitable administration route to increase the efficacy of the DNA vaccine. The result suggested that intradermal vaccination is more suitable for the DNA vaccine than intramuscular or subcutaneous vaccination.

Finally, we developed plasmid-based DNA vaccines encoding the granulysin or Ksp37. Granulysin is a member of the saposin-like protein family and colocalizes with perforin and granzymes in the cytolytic granules of human CTL and NK cells. In the presence of perforin, it has a cytolytic activity against intracellular pathogens in the cytoplasm of infected cells. It also has a cytotoxic effect on tumor cells.¹⁰⁻¹² Granulysin is present in cytoplasm of human CD8 positive cytotoxic T cells and NK cells. It has been suggested that granulysin has a cytolytic activity against *M. tuberculosis* outside macrophages and reduces the number of *M. tuberculosis* in the macrophage dependent on the presence of perforin *in vitro*.¹¹ However, the precise role of granulysin *in vivo* has not been elucidated yet. Therefore, we have established granulysin transgenic mice to elucidate *in vivo* role of granulysin and obtain the information to develop novel vaccines against *M. tuberculosis*. Transgenic mice of 15K and 9K granulysins were resistant to TB infection *in vivo*. This is the first report indicating an *in vivo* role of granulysin in the defense against the infection of TB. In addition, we demonstrated the efficacy of granulysin-vaccine in the monkey model of TB.

Ksp37 is also produced from CTL and NK cells.¹³ However, immunological function of Ksp37 has not been elucidated yet. In the first step, we first examined the amount of Ksp37 in the serum of patients with TB. The result indicated that Ksp37 in

the serum of patients with TB was lower than that of healthy volunteer. In the next step, we have established Ksp37 transgenic mice to elucidate the *in vivo* role on Ksp37 in the immunity to the infection of *M. tuberculosis*. Ksp37 transgenic mouse was resistant to the infection of TB, suggesting the anti-TB effect of Ksp37 *in vivo*.

To increase the efficacy of the vaccine, we examined the synergistic effect of the combination therapy, in which HSP65-vaccine and first line chemotherapy drug (INH) were administrated. We also examined the synergistic effect of the combination of two kinds of DNA vaccines. HSP65- and granulysin-vaccine were simultaneously administrated in the murine models of TB and efficacy of the vaccines was evaluated *in vivo*.

In parallel, we investigated the immunological effects of granulysin and Ksp37 and revealed the synergistic effect of two molecules on the induction of TB-specific CTL (manuscript submitted).

These findings demonstrated that granulysin-vaccine and Ksp37-vaccine might provide very useful weapon as TB vaccines, and those efficacy will be enhanced in combination with other DNA vaccine (including HSP65 vaccine) and INH.

Results

Novel therapeutic vaccine of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine. *Therapeutic effect of the vaccine in murine models of TB.* Therapeutic efficacy of HSP65 DNA + IL-12 DNA vaccine (HSP65-vaccine) was evaluated in murine models. At 30 d after intravenous challenge of MDR-TB, the CFUs of TB in the lungs, spleen, and liver were counted and therapeutic efficacy of HVJ-Envelope DNA vaccine was evaluated.

Table 1 shows the feature of novel TB vaccines; the vaccine consists of a plasmid DNA vaccine expressing mycobacterial heat shock protein 65 (HSP65)+interleukin-12 (IL-12) and a vector (hemagglutinating virus of Japan (HVJ)-liposome or HVJ-envelope). We used the mouse model in our previous study.^{6,7} This vaccine showed therapeutic effect against TB in the mouse: (1) This vaccine significantly decrease the number of drug sensitive H37Rv TB in the spleen and the lung of mice (data not shown). This vaccine also decreased the number of MDR-TB in the lungs and spleen of mice, indicating the efficacy of the vaccine in the mouse model of TB. (2) Significant prolongation of survival was observed in the XDR-TB infected mice. The survival period of the mouse treated with this vaccine was prolonged compared with non-vaccinated mice. Those results demonstrated that this vaccine have strong therapeutic effect against XDR-TB. (3) We have established the mouse model of chronic TB disease using an inhalation system (aerosol chamber) for the infection of TB. By using this model, therapeutic efficacy of this vaccine was examined. The vaccine was administered 5 weeks after aerosol infection of TB. Treatment with this vaccine decreased the number of TB in the lung of the mice (data not shown).

Thus, we demonstrated that this vaccine had a therapeutic effect against XDR-TB and MDR-TB as well as drug-sensitive TB.

Synergistic effect of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine in combination with INH against TB infection. To enhance the




Figure 1. Synergistic therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine and INH on TB infection of mice. BALB/c mice were infected with H37Rv TB by using intratracheal aerosol challenge using aerosol chamber. One week after challenge of TB, the vaccine and INH (0.03mg/mouse) were administered 6 times for 3 weeks. Five weeks after TB challenge, mice were sacrificed, and CFU of TB in the spleen were evaluated. G1 vs. G2; $p < 0.05$; G1 vs. G3; $p < 0.05$; G3 vs. G5; $p < 0.05$; G2 vs. G5 $p < 0.05$; Student's t test.




Figure 2. Synergistic therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine and INH on TB infection of mice. BALB/c mice were infected with H37Rv TB by using intratracheal aerosol challenge using aerosol chamber. One week after challenge of TB, the vaccine and INH (0.03mg/mouse) were administered 6 times for 3 weeks. Five weeks after TB challenge, mice were sacrificed, and CFU of TB in the liver were evaluated. G2 vs. G4; $p < 0.05$; G3 vs. G4; $p < 0.05$; Student's t test.

efficacy, we examined synergistic effect of combinational therapy of this vaccine and INH (isoniazid) on the infection of TB. The numbers of TB in the mouse spleen and liver were significantly decreased compared with the monotherapy, indicating the synergistic effect of the combinational therapy (Figs. 1 and 2).

We also compared the administration route of the vaccine to improve the regimen of the therapy. We selected three routes (intradermal, intramuscular and subcutaneous injections) for our experiment. The efficacy of intradermal administration (i.d.) was highest among three administration routes (Fig. 3).

Therefore, in the monkey model we plan to study the efficacy of intradermal injection of this vaccine, in comparison to i.m administration.

IL-2 receptor γ -chain gene disrupted SCID-PBL/hu. We have very important humanized immune model (SCID-PBL/hu) to study the human T cell immune response in vivo as reported first in Cancer Research 1997.⁴ We evaluated the efficacy of novel vaccines in vivo using this humanized immune model.

We used IL-2 receptor γ -chain gene knockout mouse-based model (NOD SCID-PBL/hu) to analyze the human T cell responses to the vaccine (Table 2).

The efficacy of HSP65+ IL-12 DNA vaccine was examined in this IL-2 receptor γ -chain gene disrupted SCID-PBL/hu-model and significant decrease of the number of TB in the liver was observed as shown in Table 2A. This model shows stronger human CTL induction and proliferation than conventional SCID mouse-based model (CB17-SCID-PBL-hu) (Table 2B).

Therapeutic efficacy of this vaccine on monkey model. We are developing a GMP level of DNA vaccine that contains two expression units in one plasmid vector for future clinical trial. In this study, we used a GMP level of DNA vaccine for the evaluation of the potency in the monkey model of TB. Monkeys were intratracheally instilled with 5×10^2 CFU of human TB (Erdman strain). After TB infection, 9 times intramuscular injection of this vaccine (total 400 μ g/monkey) was conducted. Therapeutic efficacy was evaluated on the basis of survival, ESR, body weight, immune responses, chest X-ray and PPD skin test. The monkey group treated with HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine showed 100% survival (data not shown). In contrast, the monkey group of control saline showed 60% survival. Thus, the therapeutic DNA vaccine improved the survival rate of TB-infected monkeys, compared with the saline (control).

These data indicated the therapeutic efficacy of a GMP-level of DNA vaccine in TB-infected monkeys.

Efficacy of granulysin-vaccines. Efficacy of granulysin in transgenic mice. We noticed the in vivo function of granulysin, since it shows a cytolytic activity against Mycobacterium tuberculosis. The features of granulysin are as follows:

(1) Granulysin is cytolytic molecules expressed by human CTL and NK cells and show the cytolytic activity against a variety of tumors and microbes, including Mycobacterium tuberculosis. Granulysin belongs to the saposin-like protein family that includes amoebapores and NK lysine. Recent studies show that granulysin also has chemoattractant and proinflammatory activities. However, in vivo anti-microbe activity and anti-tuberculosis activity of granulysin has not been elucidated yet.

(2) It has been reported that the granulysin has the function of in vitro cytotoxic activity against M. tuberculosis outside the macrophage cells, and contributes the in vitro reduction of M. tuberculosis in the macrophage in the presence of perforin.

(3) However, the precise role of granulysin in the in vivo against the tuberculosis infection has not been elucidated yet. Therefore, we have established granulysin transgenic mice to elucidate mechanism of granulysin in vivo. We have established two kinds of transgenic mice by using usual microinjection method: 15K granulysin transgenic mice and 9K granulysin transgenic